Dominique Le Beller
CEO of DEINOBIOTICS
immunology
deinove
Liechtenstein
Biography
Education: Biological Engineer with a Doctorate in Microbiology, Bioconversions and Enzymology (Université de Technologie de Compiègne). Career: Dominique LE BELLER spent his all career in the Pharma industry (HOESCHST-MARION-ROUSSEL, AVENTIS) researching on ati-infective agents and notably contributed to the development of 3 antibiotics: Ketek®, NXL 201 and NXL 104. With the Institut Pasteur, he also played an active role in the creation and implementation of the "Infectology" subject at the Pole MEDICEN, and launched the first "chemical library" project. In 2004,
Research Interest
Career: Dominique LE BELLER spent his all career in the Pharma industry (HOESCHST-MARION-ROUSSEL, AVENTIS) researching on ati-infective agents and notably contributed to the development of 3 antibiotics: Ketek®, NXL 201 and NXL 104. With the Institut Pasteur, he also played an active role in the creation and implementation of the "Infectology" subject at the Pole MEDICEN, and launched the first "chemical library" project. In 2004, Dominique LE BELLER co-founded Novexel and directed projects, operations and human resources at this start-up specialized in the development of anti-infective agents until it was bought by Astra Zeneca for nearly $500 million in 2010.